PepGen Ltd (PEPG)

Currency in USD
1.44
+0.06(+4.35%)
Closed·
1.440.00(0.00%)
·
PEPG is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.371.47
52 wk Range
1.017.80
Key Statistics
Prev. Close
1.38
Open
1.4
Day's Range
1.37-1.47
52 wk Range
1.01-7.8
Volume
766.38K
Average Volume (3m)
1.43M
1-Year Change
0%
Book Value / Share
1.94
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
PEPG Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
10.14
Upside
+604.37%
Members' Sentiments
Bearish
Bullish
ProTips
2 analysts have revised their earnings upwards for the upcoming period

PepGen Ltd News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Strong Buy
Moving Averages
Sell

Analyst Ratings

6 Buy
0 Hold
1 Sell
Ratings:
7 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 10.14
(+604.37% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Wedbush
Buy4.00+177.78%5.00Maintain13/05/2026
Stifel
Buy12.00+733.33%-Maintain05/03/2026
Oppenheimer
Buy15.00+941.67%-New Coverage25/02/2026
Guggenheim
Buy7.00+386.11%6.00Maintain18/02/2026
H.C. Wainwright
Buy20.00+1,288.89%18.00Maintain14/11/2025

Earnings

Latest Release
12/05/2026
EPS / Forecast
-0.26 / -0.29
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

PepGen (PEPG) Income Statement & Profits

Compare PEPG to Peers and Sector

Metrics to compare
PEPG
Peers
Sector
Relationship
P/E Ratio
−1.2x−3.5x−0.5x
PEG Ratio
−0.02−0.050.00
Price/Book
0.7x2.1x2.6x
Price / LTM Sales
-37.9x3.1x
Upside (Analyst Target)
-162.8%55.1%
Fair Value Upside
Unlock−7.5%7.2%Unlock

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
4.12M5.95%5.68M
Other Institutional Investors
88.41M94.05%122.01M
Public Companies & Retail Investors
0.000.00%0.00
Total
92.53M100.00%127.69M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Vanguard Index Funds - Vanguard Total Stock Market ETF2.04%1,408,4491,944
Vanguard Index Funds - Vanguard Extended Market ETF0.70%482,688666

People Also Watch

1.3500
INHD
+8.87%
0.39
KIDZ
-10.66%
1.7430
ELAB
-0.97%
0.880
MDXH
+4.85%

FAQ

What Is the PepGen (NASDAQ: PEPG) Share Price Today?

The PepGen stock price today is 1.44 USD.

What Stock Exchange Does PepGen (PEPG) Trade On?

PepGen is listed and trades on the Nasdaq Stock Exchange.

What Is the Ticker (Stock Symbol) for PepGen?

The stock symbol (also called a 'ticker') for PepGen is "PEPG."

What Is the Current PepGen Market Capitalisation?

As of today, PepGen (NASDAQ: PEPG) market cap is 95.45M USD.

What Is PepGen's (PEPG) Earnings Per Share (TTM)?

The PepGen EPS is currently -1.51 (Trailing Twelve Months).

When Is the Next PepGen Earnings Date?

PepGen's next earnings report will be released on 06/08/2026.

Is PEPG a Buy or Sell From a Technical Analyst Perspective?

Based on today's PepGen moving averages and other technical indicators, the daily buy/sell signal for PEPG stock is Strong Sell.

How Many Times Has PepGen Stock Split?

PepGen has split 0 times. (See the PEPG stock split history page for full effective split date and price information.)

How Many Employees Does PepGen Have?

PepGen has 56 employees, based on their latest Companies House report.

What is the current trading status of PepGen (NASDAQ: PEPG)?

As of 21/05/2026, PepGen (PEPG) is trading at a share price of 1.44 USD, with a previous close of 1.38 USD. The stock has fluctuated within a day range of 1.37 USD to 1.47 USD, while its 52-week range spans from 1.01 USD to 7.80 USD.

What Is PepGen (PEPG) Price Target According to Analysts?

The average 12-month price target for PepGen is 10.14 USD, with a high estimate of 20 USD and a low estimate of 3 USD. 6 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Strong Buy. The stock has an +604.37% Upside potential.

What Is the PEPG Premarket Price?

PEPG's last pre-market stock price is 1.40 USD. The pre-market share volume is 1,120.00, and the stock has decreased by 0.02, or 1.45%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.